Poolbeg Pharma PLC (POLB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Poolbeg Pharma PLC (POLB) has a cash flow conversion efficiency ratio of -0.251x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.16 Million ≈ $-263.05 USD) by net assets (GBX8.60 Million ≈ $1.05K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See POLB days of operational coverage to measure how many days the company can operate on defensive assets alone.
Poolbeg Pharma PLC - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Poolbeg Pharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Poolbeg Pharma PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Poolbeg Pharma PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aesthetic Medical International Holdings Group Limited
NASDAQ:PAIYY
|
-0.054x |
|
Lucky Minerals Inc
V:LKY
|
0.001x |
|
Frenkel Topping Group
LSE:FEN
|
0.040x |
|
XXL Energy Corp
V:XL
|
-0.009x |
|
Robert Walters
LSE:RWA
|
0.020x |
|
Calnex Solutions Plc
LSE:CLX
|
0.111x |
|
RightBridge Ventures Group AB
ST:RIGHTB
|
0.172x |
|
M.T.I Wireless Edge Ltd
LSE:MWE
|
0.050x |
Annual Cash Flow Conversion Efficiency for Poolbeg Pharma PLC (2021–2025)
The table below shows the annual cash flow conversion efficiency of Poolbeg Pharma PLC from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Poolbeg Pharma PLC (POLB) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX8.60 Million ≈ $1.05K |
GBX-4.51 Million ≈ $-548.49 |
-0.524x | -4.61% |
| 2024-12-31 | GBX9.27 Million ≈ $1.13K |
GBX-4.65 Million ≈ $-565.28 |
-0.501x | -65.16% |
| 2023-12-31 | GBX14.44 Million ≈ $1.76K |
GBX-4.38 Million ≈ $-533.04 |
-0.303x | -27.25% |
| 2022-12-31 | GBX18.32 Million ≈ $2.23K |
GBX-4.37 Million ≈ $-531.46 |
-0.238x | -150.83% |
| 2021-12-31 | GBX22.58 Million ≈ $2.75K |
GBX-2.15 Million ≈ $-261.11 |
-0.095x | -- |
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more